Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Trading 05-01 10:38:16 EDT

0.2481

-0.0019

-0.76%

High0.2576	Low0.2441	Vol736.92K
Open0.2569	D1 Closing0.2500	Amplitude5.40%
Mkt Cap30.02M	Tradable Cap26.05M	Total Shares121.00M
T/O183.62K	T/O Rate0.70%	Tradable Shares105.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.2481,"timestamp":1777646294142,"preClose":0.25,"halted":0,"volume":736919,"delay":0,"changeRate":-0.007600000000000051,"floatShares":105000000,"shares":121000000,"eps":-2.89,"marketStatus":"Trading","change":-0.0019,"latestTime":"05-01 10:38:16 EDT","open":0.2569,"high":0.2576,"low":0.2441,"amount":183618.93257928,"amplitude":0.054,"askPrice":0.2535,"askSize":5300,"bidPrice":0.2481,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.89,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777665600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.25,"preHourTrading":{"tag":"盘前","latestPrice":0.2569,"preClose":0.25,"latestTime":"09:26 EDT","volume":81348,"amount":20838.975730560003,"timestamp":1777642005286,"change":0.0069,"changeRate":0.0276,"amplitude":0.0548},"postHourTrading":{"tag":"盘后","latestPrice":0.2515,"preClose":0.25,"latestTime":"19:58 EDT","volume":72938,"amount":18406.677299,"timestamp":1777593485088,"change":0.0015,"changeRate":0.006,"amplitude":0.0258},"volumeRatio":1.022288,"impliedVol":0.4946,"impliedVolPercentile":0.239},"requestUrl":"/m/hq/s/OTLK","defaultTab":"news","newsList":[{"id":"2629868657","title":"Outlook Therapeutics closes USD 5 million registered direct offering at USD 0.31/share","url":"https://stock-news.laohu8.com/highlight/detail?id=2629868657","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629868657?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:14","pubTimestamp":1776975246,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics closed a registered direct offering of 16,129,033 common shares at USD 0.31 per share, raising about USD 5 million gross.Concurrent private placement issued unregistered warrants for up to 16,129,033 shares at USD 0.31 exercise price.Warrants become exercisable following stockholder approval, with expiry five years from first exercisability.Company also repriced investor warrants covering 2,142,854 shares to USD 0.31 from USD 2.26.Net proceeds earmarked primarily for working capital, general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLb5g8qd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4585","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4139","LU2210150020.SGD","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014039.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ","LU0314104364.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629850202","title":"Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2629850202","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629850202?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:05","pubTimestamp":1776974700,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., April 23, 2026  -- Outlook Therapeutics, Inc.  , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 16,129,033 shares of its common stock at an offering price of $0.31 per share of common stock. Additionally, in a concurrent private placement, the Company issued unregistered warrants to purchase up to an aggregate of 16,129,033 shares of common stock at an exercise price of $0.31 per share. The unregistered warrants will become exercisable on the later of  the date of stockholder approval of the issuance of the shares underlying the warrants and  the effective date of an amendment to the Company's certificate of incorporation to increase the authorized shares of the Company and will expire five years following the later of  the date th","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4604","BK4139","LENZ","BK4588","BK4099","BK4585","03160","TM","BK4555","OTLK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629040747","title":"Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2629040747","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629040747?lang=en_us&edition=fundamental","pubTime":"2026-04-22 22:29","pubTimestamp":1776868193,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16.129M shares o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-to-sell-16-129m-shares-at-31c-in-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-to-sell-16-129m-shares-at-31c-in-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","LENZ","BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049983","title":"Outlook Therapeutics prices 16,129,033-share registered direct offering at USD 0.31","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049983","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629049983?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:36","pubTimestamp":1776861372,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics priced a USD 5 million registered direct offering at USD 0.31 per share.Deal covers 16,129,033 common shares or pre-funded warrants in lieu of shares.Concurrent private placement includes unregistered warrants for up to 16,129,033 shares at USD 0.31 exercise price.Net proceeds earmarked for working capital, general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDLbkWF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049833","title":"Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629049833?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:30","pubTimestamp":1776861002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA2MHBTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629306379","title":"Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2629306379","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629306379?lang=en_us&edition=fundamental","pubTime":"2026-04-22 05:16","pubTimestamp":1776806180,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics ( ($OTLK) ) has shared an announcement. On April 21, 2026, Outlook Therapeutics announced that it had completed a Federal Disp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-advances-fda-dispute-on-wet-amd-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-advances-fda-dispute-on-wet-amd-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0198837287.USD","BK4605","LU1242518857.USD","BK4612","LU0127658192.USD","LU0823421333.USD","LU0081259029.USD","LU0642271901.SGD","LU0056508442.USD","TLT","IE00B5949003.HKD","LU1303367103.USD","LU2250418816.HKD","LU1989764664.SGD","LU2264538146.SGD","LU1803068979.SGD","IE00BMPRXN33.USD","BK4539","LU0390134368.USD","LU0719512351.SGD","LU0979878070.USD","LU2458330243.SGD","LU2931357623.SGD","TMF","LU2360106780.USD","LU1951198990.SGD","BK4534","LU2054465674.USD","BK4543","LU1242518931.SGD","AMDD","LU1880398554.USD","BK4139","LU0109392836.USD","LU2089985449.USD","LU0823434583.USD","AMDL","BK4529","BK4585","BK4614","AMDW","LU1852331112.SGD","AMDG","LU1951200564.SGD","BK4512","BK4554","BK4566","AMYY","LU1316542783.SGD","LU1880398471.USD","LU2458330169.SGD","DAMD","LU1064131342.USD","LU1988902786.USD","LU2098885051.SGD","AMDY","BK4532","IE0004445239.USD","LU0823421416.USD","BK4141","LU0274383776.USD","LU1861559042.SGD","BK4575","OTLK","LU0823434740.USD","LU1861558580.USD","AMDU","LU2355687059.USD","LU2860962120.EUR","IE00BMPRXR70.SGD","IE0009356076.USD","BK4007","BK4588","AMUU","LU0889565833.HKD","TLTW","LU1923623000.USD","BK4573","LU0082616367.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629452034","title":"BRIEF-Outlook Therapeutics Completes Federal Dispute Resolution (Fdr) Meeting With FDA For Ons-5010/Lytenava™ (Bevacizumab-Vikg)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629452034","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629452034?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:05","pubTimestamp":1776776759,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Completes Federal Dispute Resolution (Fdr) Meeting With FDA For Ons-5010/Lytenava (Bevacizumab-Vikg)Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS COMPLETES FEDERAL DI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nTUA2Q4N2Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629603490","title":"Outlook Therapeutics Inc - Expects FDA Feedback in May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629603490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629603490?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:05","pubTimestamp":1776776700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nTUA2Q4N2Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625696863","title":"Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2625696863","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625696863?lang=en_us&edition=fundamental","pubTime":"2026-04-08 02:11","pubTimestamp":1775585460,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics files FDA dispute on ONS-5010 after CRL citing effectiveness concerns; meeting with agency official set for April 2026.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/07/FDA-Warns-Check-Can-Codes.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/07/FDA-Warns-Check-Can-Codes.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/04/51688863/outlook-therapeutics-files-fda-resolution-request-after-rejection-for-vision-loss-drug","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/04/51688863/outlook-therapeutics-files-fda-resolution-request-after-rejection-for-vision-loss-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0128526141.USD","LU0390134368.USD","BK4007","OTLK","IE00BFMHRM44.USD","FDRR","BK4121","BK4139","BK4530","CRL","LENZ","BK4585","BK4588","LU1815336091.USD","LABU","LU0757428866.USD","BK4539","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625955505","title":"Outlook Therapeutics submits formal dispute resolution request to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2625955505","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625955505?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:19","pubTimestamp":1775567943,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced that it submitted a formal dispute resolution request to the FDA as a follow-up to its recent Type A meeting ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-submits-formal-dispute-resolution-request-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-submits-formal-dispute-resolution-request-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4539","BK4007","LENZ","BK4139","BK4588","OTLK","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953298","title":"BUZZ-Outlook Therapeutics rises as FDA agrees to review eye drug decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953298","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953298?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:01","pubTimestamp":1775566871,"startTime":"0","endTime":"0","summary":"BUZZ-Outlook Therapeutics rises as FDA agrees to review eye drug decision** Shares of drugmaker Outlook Therapeutics OTLK.O rise about 10% to $0.22 premarket** Co says it has asked the U.S. FDA to reconsider its decision not to approve its experimental eye drug ons-5010/lytenava** Co says FDA accepted a formal dispute resolution request and will meet the company later this month** Drug targets wet age-related macular degeneration, a common eye disease that causes vision loss due to leaking blood vessels in the retina** Co says data from NORSE TWO and NORSE EIGHT studies show the drug is safe and effective, with no safety concerns flagged by the FDA** Adds the drug is already approved in Europe and the UK, where commercial launches have begun** As of last close, stock down ~87% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4N40Q0X3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953674","title":"BRIEF-Outlook Therapeutics Announces Formal Dispute Resolution Request For Ons-5010/Lytenava™ (Bevacizumab-Vikg) Accepted By FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953674","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953674?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:55","pubTimestamp":1775566531,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Announces Formal Dispute Resolution Request For Ons-5010/Lytenava (Bevacizumab-Vikg) Accepted By FDAApril 7 (Reuters) - Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA3BS9QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004992","title":"Outlook Therapeutics closes $5.0 million public offering; warrants target up to $5.0 million additional proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004992","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004992?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:06","pubTimestamp":1774469166,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics closed a public offering of 20,000,000 common shares with warrants to buy up to 20,000,000 additional common shares.The combined offering price was USD 0.25 per share and accompanying warrant.Gross proceeds were USD 5.0 million, before fees and expenses.Each warrant has an exercise price of USD 0.25 and expires five years after issuance.Net proceeds are intended primarily for working capital and general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL7P6TCt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","BK4139","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","BK4588","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4112","LU2095319765.USD","LU2210149790.SGD","SG9999014005.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","OTLK","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004617","title":"Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004617","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004617?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:05","pubTimestamp":1774469100,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., March 25, 2026  -- Outlook Therapeutics, Inc. , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined public offering price of $0.25. Each common warrant has an exercise price of $0.25 per share, is exercisable immediately and expires five years from the date of issuance.The aggregate gross proceeds of the offering were $5.0 million, before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to Outlook Therapeutics from the common warrants, if fully exercised on a cash basis, will be approximately $5.0 million. No assurance can be given that any of the common wa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4099","TM","BK4585","BK4539","BK4007","LENZ","BK4139","BK4555","BK4588","OTLK","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622097434","title":"Outlook Therapeutics Shares Drop After $5 Million Public Offering Priced","url":"https://stock-news.laohu8.com/highlight/detail?id=2622097434","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622097434?lang=en_us&edition=fundamental","pubTime":"2026-03-25 02:32","pubTimestamp":1774377154,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics  shares fell 39% in Tuesday trading after the company priced a public offering of 20 million shares at $0.25 each for gross proceeds of $5 million.Intraday volume topped 22.9 million shares versus the daily average of 5.33 million.Price: 0.19, Change: -0.13, Percent Change: -39.59","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","OTLK","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621306626","title":"Outlook Therapeutics prices USD 5 million public offering at USD 0.25 per share with warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2621306626","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621306626?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:01","pubTimestamp":1774350085,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics priced a public offering of 20,000,000 common shares with warrants to buy up to 20,000,000 additional shares.The combined offering price is USD 0.25 per share and accompanying warrant, for expected gross proceeds of USD 5.0 million.Warrants have an exercise price of USD 0.25 per share and expire five years after issuance.Closing is expected on or about March 25, 2026, subject to customary conditions.Net proceeds are intended primarily for working capital and general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL2jWWLy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","NDAQ","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU2095319765.USD","BK4112","SG9999014013.SGD","BK4139","SG9999014039.USD","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","LU2210150020.SGD","BK4588","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621664330","title":"Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2621664330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621664330?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:00","pubTimestamp":1774350005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nTUA5DPS1D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621871430","title":"BRIEF-Outlook Therapeutics Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2621871430","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621871430?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:31","pubTimestamp":1774301488,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Announces Proposed Public OfferingMarch 23 (Reuters) - Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERINGSource text: ID:nGNX5pQbgxFurther company coverage: OTLK.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUA3BFNT2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621871150","title":"Outlook Therapeutics launches best-efforts public offering of common stock and warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2621871150","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621871150?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:30","pubTimestamp":1774301423,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics commenced a best-efforts public offering of common stock or pre-funded warrants, along with accompanying warrants exercisable for common stock.H.C. Wainwright is acting as the exclusive placement agent for the offering.Net proceeds are intended to be used primarily for working capital and general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL2Mr1yk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","SG9999014039.USD","IE00BKPKM429.USD","BK4139","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4588","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU0314104364.USD","LU2210149790.SGD","OTLK","LU2210150020.SGD","IE00BN0W2V16.EUR","BK4585","NDAQ","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621808768","title":"Outlook Therapeutics Launches LYTENAVA in Germany and the UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2621808768","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621808768?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:19","pubTimestamp":1774300793,"startTime":"0","endTime":"0","summary":"Outlook said LYTENAVA  is approved in the EU and the UK for wet age-related macular degeneration, positioning the company to compete in a market where off-label bevacizumab is widely used.The company reported it launched directly in Germany and the UK in June 2025 and is planning additional EU launches either directly or through licensing partners.Outlook estimated the EU anti-VEGF retina market at about USD 3.6 billion and the US anti-VEGF retina market at about USD 8.5 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLszVrK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1286},{"period":"1month","weight":0.2148},{"period":"3month","weight":-0.4314},{"period":"6month","weight":-0.8016},{"period":"1year","weight":-0.8408},{"period":"ytd","weight":-0.8418}],"compareEarnings":[{"period":"1week","weight":0.0144},{"period":"1month","weight":0.1051},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.0537},{"period":"1year","weight":0.296},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.1402},{"month":3,"riseRate":0.3,"avgChangeRate":-0.095662},{"month":4,"riseRate":0.5,"avgChangeRate":-0.0707},{"month":5,"riseRate":0.666667,"avgChangeRate":0.154179},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.046947},{"month":7,"riseRate":0.6,"avgChangeRate":0.042124},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction